Pelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment

Reuters

2025/09/04

Pelthos <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment

Pelthos Therapeutics Inc. has released its latest investor presentation, highlighting key aspects of its corporate profile and recent developments. The company, trading under the ticker PTHS, has a stock price of $23.65 and a market capitalization of approximately $205 million. Pelthos recently launched Zelsuvmi, a treatment for Molluscum contagiosum, marking the first at-home treatment option for this contagious viral disease. The addressable market for this treatment is valued at over $20 billion, with up to 6 million annual cases in the U.S. Pelthos aims for a peak net revenue forecast of $175 million per annum by 2028. The management team, led by CEO Scott Plesha, has extensive experience in successful drug launches. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564300314"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564300314\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564300314?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 04:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564300314","market":"nz","top_or_hot":-1,"title":"Pelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pelthos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pelthos Therapeutics Inc. has released its latest investor presentation, highlighting key aspects of its corporate profile and recent developments. The company, trading under the ticker PTHS, has a stock price of $23.65 and a market capitalization of approximately $205 million. Pelthos recently launched Zelsuvmi, a treatment for Molluscum contagiosum, marking the first at-home treatment option for this contagious viral disease. The addressable market for this treatment is valued at over $20 billion, with up to 6 million annual cases in the U.S. Pelthos aims for a peak net revenue forecast of $175 million per annum by 2028. The management team, led by CEO Scott Plesha, has extensive experience in successful drug launches. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-04 04:50</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pelthos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pelthos Therapeutics Inc. has released its latest investor presentation, highlighting key aspects of its corporate profile and recent developments. The company, trading under the ticker PTHS, has a stock price of $23.65 and a market capitalization of approximately $205 million. Pelthos recently launched Zelsuvmi, a treatment for Molluscum contagiosum, marking the first at-home treatment option for this contagious viral disease. The addressable market for this treatment is valued at over $20 billion, with up to 6 million annual cases in the U.S. Pelthos aims for a peak net revenue forecast of $175 million per annum by 2028. The management team, led by CEO Scott Plesha, has extensive experience in successful drug launches. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL7K5rvN:1","article_id":"2564300314","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564300314","pubTimestamp":1756932625,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pelthos Therapeutics Inc. has released its latest investor presentation, highlighting key aspects of its corporate profile and recent developments. The company, trading under the ticker PTHS, has a stock price of $23.65 and a market capitalization of approximately $205 million. Pelthos recently launched Zelsuvmi, a treatment for Molluscum contagiosum, marking the first at-home treatment option for this contagious viral disease. The addressable market for this treatment is valued at over $20 billion, with up to 6 million annual cases in the U.S. Pelthos aims for a peak net revenue forecast of $175 million per annum by 2028. The management team, led by CEO Scott Plesha, has extensive experience in successful drug launches. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PTHS":"PELTHOS THERAPEUTICS INC"},"translate_title":"Pelthos Therapeutics Inc.发布投资者演示文稿，重点介绍用于传染性软疣治疗的Zelsuvmi的推出","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTHS":0.9},"content_text":"Pelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment\n    \n\n        Pelthos Therapeutics Inc. has released its latest investor presentation, highlighting key aspects of its corporate profile and recent developments. The company, trading under the ticker PTHS, has a stock price of $23.65 and a market capitalization of approximately $205 million. Pelthos recently launched Zelsuvmi, a treatment for Molluscum contagiosum, marking the first at-home treatment option for this contagious viral disease. The addressable market for this treatment is valued at over $20 billion, with up to 6 million annual cases in the U.S. Pelthos aims for a peak net revenue forecast of $175 million per annum by 2028. The management team, led by CEO Scott Plesha, has extensive experience in successful drug launches. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}